Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
NCT05623410
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
300
Enrollment
INDUSTRY
Sponsor class
Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL:
ATGC-110
BIOLOGICAL:
Xeomin®
Sponsor
ATGC Co., Ltd.